Target
Platinum-based chemotherapy
37 abstracts
Abstract
Neoadjuvant immunochemotherapy for locally advanced hypopharyngeal squamous cell carcinoma: Pooled results analysis from two prospective single-arm phase 2 trials.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
Comparison of pembrolizumab plus chemotherapy versus concurrent or sequential radiochemotherapy in patients with driver mutation-lacking lung adenocarcinoma presenting with recurrent laryngeal nerve invasion leading to hoarseness.Org: Jiangmen, China,
Abstract
VELOCITY-Lung substudy-03: A phase 2 study of neoadjuvant domvanalimab (dom)+zimberelimab (zim)+chemotherapy (chemo) or zim+chemo followed by adjuvant dom+zim or zim in patients with resectable stage II-III non-small cell lung cancer (NSCLC).Org: Fort Wayne Medical Oncology and Hematology, Christian Hospital, University Hospitals Birmingham NHS Foundation Trust, Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS), Shaare Zedek Medical Center,
Abstract
Benchmarking the transcriptomic predictive biomarkers for immunotherapy plus chemotherapy: Results from phase III RATIONALE-309 and ORIENT-11 randomized trials.Org: Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China, Shantou University Medical College, Shantou, China,
Abstract
Effectiveness and safety analysis of serplulimab-based regimens in patients with HER2-negative advanced gastric cancer from a real-world retrospective study.Org: the Fourth Affiliated Hospital of Soochow University,
Abstract
Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): Minimum 3-year survival follow-up.Org: Maria Sklodowska-Curie National Cancer Research Institute,
Abstract
A phase I clinical study to evaluate the safety, tolerability, immunogenicity, pharmacokinetics and preliminary efficacy of SCB-219M in patients with chemotherapy-induced thrombocytopenia (CIT): An interim analysis.Org: Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, The Sixth People's Hospital of Chengdu,
Abstract
Comparative analysis of pembrolizumab and cetuximab-based therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma: Real-world data.Org: Massey Comprehensive Cancer Center, Division of Hematology, Oncology, and Palliative Care,
Abstract
First-line immunotherapy plus chemotherapy for ES-SCLC: Comparison between PD-1 and PD-L1 inhibitors in a real-world setting.Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China, Shandong Cancer Hospital, Shandong First Medical University, Jinan, China,
Abstract
Weekly paclitaxel (P), carboplatin (CP) plus pembrolizumab (PMB) as first-line treatment of recurrent or metastatic (R/M) or locally very advanced (LVA) head and neck squamous cell carcinoma (HNSCC): A retrospective study in 39 patients (pts).Org: Institut de Cancérologie Strasbourg Europe,
Abstract
Real-world first-line serplulimab-based immunochemotherapy for extensive-stage small cell lung cancer: The multicenter ASTRUM-005R study.Org: Department of Thoracic Medical Oncology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Department of Respiratory and Critical Care Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China, Shanxi Cancer Hospital (Shanxi Cancer Institute), Cancer Hospital of Chinese Academy of Medical Sciences Shanxi Hospital, Shanxi Medical University Affiliated Hospital, Taiyuan, China, Department of Chest Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China, Cancer Center, the 10th Affiliated Hospital of Southern Medical University (Dongguan People's Hospital), Southern Medical University, Dongguan, China,
Abstract
Exploratory biomarker analysis of the phase 3 KEYNOTE-604 study of pembrolizumab plus etoposide for extensive-stage SCLC.Org: Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Memorial Sloan Kettering Cancer Center, Vall d’Hebron University Hospital/VHIO, Lausanne University Hospital, William Osler Health System,
Abstract
Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies.Org: Centre Léon Bérard, Centre Paul Strauss, CH Bretagne, Centre Henri Becquerel, Clinique des Ormeaux,
Abstract
Associations between patient-reported nutritional status, survival, and toxicity among patients with limited stage small-cell lung cancer (LS SCLC) in a randomized trial of high-dose, twice-daily (BID) thoracic radiotherapy (TRT).Org: University of Bergen, Norwegian University of Science and Technology (NTNU), Department of Oncology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway, Sykehuset Innlandet,
Abstract
The prognostic value of patient reported outcomes (PROs) and clinical/demographic variables in the CASPIAN study.Org: University of Nebraska Medical Center, AstraZeneca,
Abstract
Final survival analysis of the phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in ovarian cancer after ten year follow-up.Org: Biometrics Department, Department of Gynecological Oncology, Sint Antonius Hospital, Department of Gynecology and Obstetrics, Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, IOV - Istituto Oncologico Veneto IRCCS -IOV,
Abstract
Neoadjuvant tislelizumab combined with APF for patients with locally advanced head and neck squamous cell carcinoma: A prospective single-arm clinical trial.Org: The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University,
Abstract
Disease outcomes by race in patients with high-risk triple negative breast cancer with residual disease after neoadjuvant chemotherapy: A post-hoc analysis of the EA1131 randomized clinical trial.Org: Brigham and Women's Hospital/Massachusetts General Hospital, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Dana-Farber Cancer Institute, MD Anderson Cancer Center, Division of Breast Surgery,
Abstract
Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in patients with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC).Org: University of Pennsylvania, Stanford Cancer Center,
Abstract
Alliance A022102: Randomized phase III trial of mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA).Org: Dana-Farber Cancer Institute, Alliance Statistics and Data Management Center, Mayo Clinic, University of Nebraska Medical Center, Sanford Health,
Abstract
Patterns of ovarian cancer care in an elderly population in Australia: A prospective cohort study from the National Gynaecology Oncology Registry (NGOR).Org: Monash University School of Public Health and Preventive Medicine, Cancer Research Program, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Peter MacCallum Cancer Centre, Melbourne, Australia, The Royal Women's Hospital, Epworth Healthcare,
Abstract
Effectiveness and safety of camrelizumab in advanced esophageal cancer: A prospective multicenter observational cohort studies (ESCORT-RWS).Org: Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, Beijing InnoCare Pharma Tech, China National Biotec Group, Changzhi People's Hospital Affiliated to Changzhi Medical College, Changzhi City,
Abstract
Initial chemotherapy for locally advanced and metastatic NUT carcinoma: A report from the NUT Carcinoma Registry.Org: Dana-Farber Cancer Institute, Boston, MA, Brigham and Women's Hospital/Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, New York, NY,
Abstract
Dares: A phase II trial of durvalumab and ablative radiation in extensive stage small cell lung cancer.Org: University of Chicago Medical Center, Chicago, IL, University of Kansas Medical Center, Department of Biostatistics & Data Science, University of Kansas Medical Center (KUMC), Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, University of Chicago,
Abstract
Peripheral myeloid cells as prognostic markers in patients (pts) with non-small cell lung cancer (NSCLC) treated with cemiplimab: Pooled analysis of EMPOWER-Lung 1 and EMPOWER-Lung 3 phase 3 trials.Org: Johns Hopkins Kimmel Cancer Center, Regeneron Pharmaceuticals, Inc., Department of Nuclear Medicine Zürich, University Hospital of Zürich, Department of Medical Oncology, Başkent University, High Technology Medical Centre, University Clinic,
Abstract
Characteristics and clinical outcome of BRCA germline mutation carriers with advanced breast cancer treated with PARP (poly ADP-ribose polymerase) inhibitors: A single institution experience.Org: University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center,
Abstract
Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.Org: Hôpitaux Nord-Ouest, Univ Rouen Normandie, LITIS Lab QuantIF team EA4108, CHU Rouen, Inserm CIC-CRB 1404,
Abstract
Neoadjuvant chemotherapy followed by definitive chemoradiation in technically unresectable oral cavity squamous cancers.Org: Tata Memorial Hospital (HBNI), Tata Memorial Centre,
Abstract
Phase II trial of safety and efficacy of tislelizumab plus chemotherapy in stage II-IV non small cell lung cancer (LungMark).Org: Department of Thoracic Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China, Laboratory of Drug Metabolism and Pharmacokinetics, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China, Guangzhou, China, Department of Thoracic Surgery, Jiangmen Central Hospital, Jiangmen, China, Department of Thoracic Surgery, Cancer Center of Guangzhou Medical University, Guangzhou, China,
Abstract
Docetaxel as a subsequent line after progression to platinum-based chemotherapy and immunotherapy.Org: Hospital Puerta de Hierro Majadahonda, Majadahonda, Spain, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigacion Sanitaria Puerta de Hierro - Segovia de Arana, Puerta de Hierro Majadahonda University Hospital, Majadahonda, Spain, H Puerta De Hierro (Spain), Madrid, Spain,
Abstract
Platinum-based chemotherapy in patients with castration-resistant prostate cancer and hepatic metastases.Org: Martini-Clinic, Prostate Cancer Center Hamburg and Department of Oncology, University Hospital Hamburg Eppendorf, Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, Rechts der Isar Medical Center,
Abstract
The evolution of treatment patterns in patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) and clinical outcomes: Results of a longitudinal observational cohort study in England.Org: Merck, Health Data Insight CIC, NHS Digital,
Abstract
Multiple antigen stimulating cellular therapy (MASCT)-I for metastatic urothelial carcinoma (mUC): A multicenter, phase I study (MASCT-I-1001).Org: Sun Yat-sen University Cancer Center Gansu Hospital, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China,
Abstract
Prognostic value of systemic immune-inflammation index in patients with locally advanced cervical cancer.Org: Hospital Universitario "Dr. José Eleuterio González", Monterrey, NL, Mexico, Centro Universitario Contra el Cáncer UANL, Monterrey, NL, Mexico, Centro Universitario Contra el Cáncer UANL, Monterrey, Mexico, Universidad Autónoma de Nuevo León, Monterrey, NL, Mexico, Centro Universitario Contra el Cáncer, Universidad Autónoma de Nuevo León, Monterrey, NL, Mexico,
Abstract
The role of adjuvant chemotherapy (CT) for early stage resectable node negative small cell lung cancer with size of ≤ 2 cm post-surgical resection: A SEER plus based statistical analysis.Org: BronxCare Health System, Bronx-Lebanon Hospital Center, Mount Sinai Hospital, Wayne State Univ/DMC Sinai Grace Hospital, Barbara Ann Karmanos Cancer Institute,
Abstract
First-line pembrolizumab plus platinum-pemetrexed in metastatic non-small cell lung cancer: Clinical experience in a Spanish tertiary hospital.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Hospital Universitario de Cruces, Hospital Universitario Donostia-Biodonostia, Hospital Universitario Cruces, Cruces University Hospital,